Sentences with phrase «cancers tested positive»

The study revealed that 14 percent of patients with oropharyngeal cancers tested positive for HCV antibodies, compared to just 6.5 percent in the control group.

She later found that whereas from 1984 to 1989 in the U.S. only 16 percent of oropharyngeal cancers tested positive for HPV, by 2005 that figure had skyrocketed to 73 percent.

Not exact matches

The national cost of false - positive tests and overdiagnosed breast cancer is estimated at $ 4 billion a year, according to a 2015 study in Health Affairs.

They suggest most women in their 40s should not have routine mammograms because the tests may cause more harm than good because of false positive results (follow - up testing proves negative for cancer).

The other, a former White House aide to President Obama, tested positive for the BRCA2 gene mutation that has led to breast cancer in her family for generations — and is taking aggressive steps to avoid the same fate.

But then again, the thousands of false positives on a cancer screening also suffer in some ways, the emotional stress, the follow - up testing, etc..

Months after water in Newburgh tested positive for elevated rates of a toxic, cancer - linked chemical, the state does not have a plan to conduct blood tests for thousands of residents who likely consumed the polluted water for years.

Iona's aunts Wanda and Lupita, who had tested positive for the mutation in 2007, were diagnosed with breast cancer in 2009.

Thus, measures of CA 125 can not be trusted to give an accurate diagnosis of cancer — and yet a number of women who tested positive apparently feared the possibility of cancer so much that they decided to have their healthy ovaries removed anyway.

They found that patients whose tumors tested positive for ER and PR, but negative for HER2, were less likely to see their cancer come back.

Because ovarian cancer is relatively rare, occurring in approximately one out of every 2,500 women, a test with only 99 percent specificity would result in false - positive diagnoses for 25 women, leading to unnecessary and risky surgeries and procedures.

However, reports of rare HPV - negative, Pap - test - positive cancers are motivating continued use of both tests (cotesting) despite increased testing costs.

Dr. Catalona, who was the first physician in the U.S. to run the phi test, added, «However, the problem is that higher levels of PSA can also be caused by a benign enlargement or inflammation of the prostate, leading to many false ‐ positives for cancer and ultimately unnecessarily invasive biopsies and an increased potential for patient harm.»

HPV - negative / Pap test - positive results preceded only small fractions of cases of precancer (3.5 %) and cancer (5.9 %); these cancers were more likely to be regional or distant stage than other cases.

HPV testing was statistically significantly more likely to be positive for cancer at any time point, except within 12 months.

Women with a family history of two or more immediate family members (mother, sister, daughter) with breast or ovarian cancer or with a positive genetic test for mutations in the BRCA1 or BRCA2 genes may be advised to consider having both breasts removed, because they are at high risk of a new cancer developing in the other breast.

In their recent study, the researchers took a retrospective look at 697 patients who'd received transplants at Seattle Cancer Care Alliance, Fred Hutch's clinical care partner, between 1993 and 2015 and who had also tested positive for rhinovirus.

Provide example data from experiments using PD - L1 positive tumors and a cancer cell - line engraftment into a humanized mouse model that was used to test anti-PD1 immune therapy

They tested DBT and DM according to four outcomes — true positive (TP), true negative (TN), false positive (FP), and false negative (FN) rates — by comparing the Breast Imaging Reporting and Data System (BI-RADS) score (assigned at screening with data about subsequent cancer diagnosis).

Of 56 patients with upper tract urothelial cancer, 75 percent tested positive using UroSEEK, including 79 percent of those with noninvasive tumors.

A team including scientists at The Institute of Cancer Research, London, found that women whose breast cancer had begun to spread and who tested positive in the αB - crystallin test were three times more likely to have disease that spread to the brain than those who tested negCancer Research, London, found that women whose breast cancer had begun to spread and who tested positive in the αB - crystallin test were three times more likely to have disease that spread to the brain than those who tested negcancer had begun to spread and who tested positive in the αB - crystallin test were three times more likely to have disease that spread to the brain than those who tested negative.

Patients with HCV - positive head and neck cancers were more likely to also test positive for HPV.

Women who tested positive for circulating tumour DNA were at 12 times the risk of relapse of those who tested negative, and the return of their cancer was detected an average of 7.9 months before any visible signs emerged.

«To our surprise, we saw a number of head and neck cancer patients who tested positive for the hepatitis C virus.

Herceptin works by blocking the receptors for the protein produced by the cancer - causing HER2 gene for those who test positive for her2 overproduction, but it does nothing for patients who are negative.

By December 2007 Shaw had joined the clinical team testing Xalkori at Mass General and soon enrolled her first few ALK - positive lung cancer patients.

For years researchers have been developing molecular imaging techniques that visualize hormonally active breast cancer cells — specifically those testing positive for human epidermal growth factor receptor 2 (HER2).

While past attempts to treat melanoma failed to meet expectations, an international team of researchers are hopeful that a compound they tested on both mice and on human cells in a petri dish takes a positive step toward creating a drug that can kill melanoma cancer cells without harming nearby healthy cells.

The new test, which examines cancer - related DNA and proteins in the blood, yielded a positive result about 70 % of the time across eight common cancer types in more than 1000 patients whose tumors had not yet spread.

A literature review finds an increased risk of cancer, late - stage cancer, and mortality, with increased waiting time between a positive screening and start of diagnostic testing.

«These results have driven us to update our treatment guidelines in Denmark to include testing with Prosigna as part of the workup of postmenopausal women with early stage HR - positive / Her -2 negative breast cancer, including patients with node - positive disease.»

Women who have had breast cancer or who have tested positive for inherited mutations in BRCA1 or BRCA2 genes are at increased risk.

Identification of those men at greatest risk for prostate cancer development and progression would provide a means of targeted screening, thereby reducing unnecessary testing, false positive tests, and the burden of overdiagnosis and over treatment.

However, knowing you test positive for one of these mutations is not a guarantee that you will develop breast cancer — and knowing you are negative doesn't guarantee that you won't develop it.

About one in 100 men who test positive for BRCA1 mutations will develop cancer in their lifetimes, while the risk for men with a BRCA2 mutation is about six in 100.

The test also predicts which women are more likely to develop ER - positive breast cancer if they develop cancer at all.

The researchers tested whether stromal tumor infiltrating lymphocytes (TILs) and other immune cells might predict responses to therapy in a set of 30 HER2 - positive breast cancer tissues treated with TCHP (26 patients) or with TCH without pertuzumab (4 patients).

GEP testing is recommended for patients with early - stage, node - negative, estrogen receptor (ER)-- positive, human epidermal growth factor 2 (HER2)-- negative cancers.

Some people, including women who test positive for a BRCA gene mutation, may be offered treatment options, such as preventive surgery, to reduce cancer risk.

The authors built a statistical simulation model to estimate the 25 - year incremental costs per quality - adjusted life - year (QALY) for Oncotype DX testing in order to evaluate the cost - effectiveness of GEP testing among patients with early - stage ER - positive / HER2 - negative breast cancer treated in community oncology practices.

«This classification test is not yet widely available in the clinic, and more testing is required to confirm these results, but nevertheless these are exciting and positive findings that could potentially change the way we select treatment for colon cancer patients in the near future,» says Dr Jennifer Mooi, medical oncologist and researcher.

In prior studies, the researchers tested the virus on a variety of breast cancers that represent degrees of aggressiveness and on human papillomavirus - positive cervical cancer cells.

They will perform preliminary studies to prepare for large - scale testing, conduct related studies to support specific trials, provide mentoring for junior faculty, and help recruit appropriate patients to Network trials, especially those expected to have a significant positive impact on cancer treatment.

This has led to an uptake of 80 % of test - positive individuals reaching GMI's Center for Personalized Genetic Healthcare, and an effective strategy for identifying the majority of adult - onset heritable colon cancer (Lynch syndrome).

Actress Angelina Jolie made waves today with her announcement that she recently had both of her breasts removed after testing positive for the BRCA 1 gene mutation — a surgery that she says cut her risk of breast cancer from 87 percent to less than 5 percent.

On the plus side, Aisner points out, testing via circulating tumor DNA returns very few false - positives — when a test discovers DNA with a cancer - causing genetic change, it is strong evidence that this alteration is, in fact, present in the patient's cancer.

April 10, 2018 - The technology is proven to be up to 40 percent more accurate than 2D mammography in locating invasive cancers, as well as reducing false - positive findings and the need for additional tests.

The NPR story reported that another recent study found that the false - positive rate for lung CT (computerized tomography) is 33 percent among those who have had two screening tests — higher than the National Cancer Institute trial found.

If a patient tests positive for an abnormal BRCA1 or BRCA2 gene and have never had breast cancer, there is a much higher - than - average risk of developing the deadly disease.

Mar. 12, 2015 — Melanoma patients whose tumors test positive for mutations in the NRAS gene were more likely to benefit from new immunotherapy drugs, according to a new study led by Vanderbilt - Ingram Cancer Center (VICC) investigators.